Analysis of vaccination campaign effectiveness and population immunity to support and sustain polio elimination in Nigeria

The world is closer than ever to a polio-free Africa. In this end-stage, it is important to ensure high levels of population immunity to prevent polio outbreaks. Here, we introduce a new method of assessing vaccination campaign effectiveness and estimating immunity at the district-level. We demonstr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC medicine 2016-03, Vol.14 (60), p.60-60, Article 60
Hauptverfasser: Upfill-Brown, Alexander M, Voorman, Arend, Chabot-Couture, Guillaume, Shuaib, Faisal, Lyons, Hil M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 60
container_issue 60
container_start_page 60
container_title BMC medicine
container_volume 14
creator Upfill-Brown, Alexander M
Voorman, Arend
Chabot-Couture, Guillaume
Shuaib, Faisal
Lyons, Hil M
description The world is closer than ever to a polio-free Africa. In this end-stage, it is important to ensure high levels of population immunity to prevent polio outbreaks. Here, we introduce a new method of assessing vaccination campaign effectiveness and estimating immunity at the district-level. We demonstrate how this approach can be used to plan the vaccination campaigns prospectively to better manage population immunity in Northern Nigeria. Using Nigerian acute flaccid paralysis surveillance data from 2004-2014, we developed a Bayesian hierarchical model of campaign effectiveness and compared it to lot-quality assurance sampling data. We then used reconstructed sero-specific population immunity based on campaign history and compared district estimates of immunity to the occurrence of confirmed poliovirus cases. Estimated campaign effectiveness has improved across northern Nigeria since 2004, with Kano state experiencing an increase of 40 % (95 % CI, 26-54 %) in effectiveness from 2013 to 2014. Immunity to type 1 poliovirus has increased steadily. On the other hand, type 2 immunity was low and variable until the recent use of trivalent oral polio vaccine. We find that immunity estimates are related to the occurrence of both wild and vaccine-derived poliovirus cases and that campaign effectiveness correlates with direct measurements using lot-quality assurance sampling. Future campaign schedules highlight the trade-offs involved with using different vaccine types. The model in this study provides a novel method for assessing vaccination campaign performance and epidemiologically-relevant estimates of population immunity. Small-area estimates of campaign effectiveness can then be used to evaluate prospective campaign plans. This modeling approach could be applied to other countries as well as other vaccine preventable diseases.
doi_str_mv 10.1186/s12916-016-0600-z
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4812602</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A448073572</galeid><sourcerecordid>A448073572</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-9cfe790df3223c2bf9a4a57ac89b767376ecc86cb9624a4a6a270192bf94e2e63</originalsourceid><addsrcrecordid>eNptklFrFDEQxxdRbK1-AF8kIIgvW5PsJtm8CEdpVSj6os8hl5vcpWSTdZM9uPv0ZnttuZMShoSZ3_8_ZJiqek_wJSEd_5IIlYTXeA6Ocb1_UZ0T0ZJaYMJeHr3Pqjcp3WFMmRDt6-qMCkwla9h5tV8E7XfJJRQt2mpjXNDZxYCM7gft1gGBtWCy20KAlJAOKzTEYfIHyvX9FFzeoRxRmoYhjvkeSVPK2oWCehcReNc_-pbkT7eG0em31SurfYJ3D_dF9efm-vfV9_r217cfV4vb2jDKci2NBSHxyjaUNoYurdStZkKbTi4FF43gYEzHzVJy2pYS1-V3RM5gCxR4c1F9PfgO07KHlYGQR-3VMLpejzsVtVOnleA2ah23qu0I5ZgWg88PBmP8O0HKqnfJgPc6QJySIkII2XHBmoJ-_A-9i9NYRjxTUnQMs_aIWmsPygUbS18zm6pF23ZYNEzMbS-focpZQe9MDGBdyZ8IPh0JNqB93qTop3nu6RQkB9CMMaUR7NMwCFbzZqnDZik8R9kstS-aD8dTfFI8rlLzD9lZywM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1797850543</pqid></control><display><type>article</type><title>Analysis of vaccination campaign effectiveness and population immunity to support and sustain polio elimination in Nigeria</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SpringerNature Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Upfill-Brown, Alexander M ; Voorman, Arend ; Chabot-Couture, Guillaume ; Shuaib, Faisal ; Lyons, Hil M</creator><creatorcontrib>Upfill-Brown, Alexander M ; Voorman, Arend ; Chabot-Couture, Guillaume ; Shuaib, Faisal ; Lyons, Hil M</creatorcontrib><description>The world is closer than ever to a polio-free Africa. In this end-stage, it is important to ensure high levels of population immunity to prevent polio outbreaks. Here, we introduce a new method of assessing vaccination campaign effectiveness and estimating immunity at the district-level. We demonstrate how this approach can be used to plan the vaccination campaigns prospectively to better manage population immunity in Northern Nigeria. Using Nigerian acute flaccid paralysis surveillance data from 2004-2014, we developed a Bayesian hierarchical model of campaign effectiveness and compared it to lot-quality assurance sampling data. We then used reconstructed sero-specific population immunity based on campaign history and compared district estimates of immunity to the occurrence of confirmed poliovirus cases. Estimated campaign effectiveness has improved across northern Nigeria since 2004, with Kano state experiencing an increase of 40 % (95 % CI, 26-54 %) in effectiveness from 2013 to 2014. Immunity to type 1 poliovirus has increased steadily. On the other hand, type 2 immunity was low and variable until the recent use of trivalent oral polio vaccine. We find that immunity estimates are related to the occurrence of both wild and vaccine-derived poliovirus cases and that campaign effectiveness correlates with direct measurements using lot-quality assurance sampling. Future campaign schedules highlight the trade-offs involved with using different vaccine types. The model in this study provides a novel method for assessing vaccination campaign performance and epidemiologically-relevant estimates of population immunity. Small-area estimates of campaign effectiveness can then be used to evaluate prospective campaign plans. This modeling approach could be applied to other countries as well as other vaccine preventable diseases.</description><identifier>ISSN: 1741-7015</identifier><identifier>EISSN: 1741-7015</identifier><identifier>DOI: 10.1186/s12916-016-0600-z</identifier><identifier>PMID: 27029535</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Africa ; Bayes Theorem ; Care and treatment ; Complications and side effects ; Geographic information systems ; Health aspects ; Humans ; Initiatives ; Nigeria - epidemiology ; Poliomyelitis ; Poliomyelitis - epidemiology ; Poliomyelitis - immunology ; Poliomyelitis - prevention &amp; control ; Poliovirus Vaccine, Oral ; Prospective Studies ; Quality control ; Vaccination ; Vaccines</subject><ispartof>BMC medicine, 2016-03, Vol.14 (60), p.60-60, Article 60</ispartof><rights>COPYRIGHT 2016 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2016</rights><rights>Upfill-Brown et al. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-9cfe790df3223c2bf9a4a57ac89b767376ecc86cb9624a4a6a270192bf94e2e63</citedby><cites>FETCH-LOGICAL-c525t-9cfe790df3223c2bf9a4a57ac89b767376ecc86cb9624a4a6a270192bf94e2e63</cites><orcidid>0000-0002-0325-006X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812602/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812602/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27029535$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Upfill-Brown, Alexander M</creatorcontrib><creatorcontrib>Voorman, Arend</creatorcontrib><creatorcontrib>Chabot-Couture, Guillaume</creatorcontrib><creatorcontrib>Shuaib, Faisal</creatorcontrib><creatorcontrib>Lyons, Hil M</creatorcontrib><title>Analysis of vaccination campaign effectiveness and population immunity to support and sustain polio elimination in Nigeria</title><title>BMC medicine</title><addtitle>BMC Med</addtitle><description>The world is closer than ever to a polio-free Africa. In this end-stage, it is important to ensure high levels of population immunity to prevent polio outbreaks. Here, we introduce a new method of assessing vaccination campaign effectiveness and estimating immunity at the district-level. We demonstrate how this approach can be used to plan the vaccination campaigns prospectively to better manage population immunity in Northern Nigeria. Using Nigerian acute flaccid paralysis surveillance data from 2004-2014, we developed a Bayesian hierarchical model of campaign effectiveness and compared it to lot-quality assurance sampling data. We then used reconstructed sero-specific population immunity based on campaign history and compared district estimates of immunity to the occurrence of confirmed poliovirus cases. Estimated campaign effectiveness has improved across northern Nigeria since 2004, with Kano state experiencing an increase of 40 % (95 % CI, 26-54 %) in effectiveness from 2013 to 2014. Immunity to type 1 poliovirus has increased steadily. On the other hand, type 2 immunity was low and variable until the recent use of trivalent oral polio vaccine. We find that immunity estimates are related to the occurrence of both wild and vaccine-derived poliovirus cases and that campaign effectiveness correlates with direct measurements using lot-quality assurance sampling. Future campaign schedules highlight the trade-offs involved with using different vaccine types. The model in this study provides a novel method for assessing vaccination campaign performance and epidemiologically-relevant estimates of population immunity. Small-area estimates of campaign effectiveness can then be used to evaluate prospective campaign plans. This modeling approach could be applied to other countries as well as other vaccine preventable diseases.</description><subject>Africa</subject><subject>Bayes Theorem</subject><subject>Care and treatment</subject><subject>Complications and side effects</subject><subject>Geographic information systems</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Initiatives</subject><subject>Nigeria - epidemiology</subject><subject>Poliomyelitis</subject><subject>Poliomyelitis - epidemiology</subject><subject>Poliomyelitis - immunology</subject><subject>Poliomyelitis - prevention &amp; control</subject><subject>Poliovirus Vaccine, Oral</subject><subject>Prospective Studies</subject><subject>Quality control</subject><subject>Vaccination</subject><subject>Vaccines</subject><issn>1741-7015</issn><issn>1741-7015</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptklFrFDEQxxdRbK1-AF8kIIgvW5PsJtm8CEdpVSj6os8hl5vcpWSTdZM9uPv0ZnttuZMShoSZ3_8_ZJiqek_wJSEd_5IIlYTXeA6Ocb1_UZ0T0ZJaYMJeHr3Pqjcp3WFMmRDt6-qMCkwla9h5tV8E7XfJJRQt2mpjXNDZxYCM7gft1gGBtWCy20KAlJAOKzTEYfIHyvX9FFzeoRxRmoYhjvkeSVPK2oWCehcReNc_-pbkT7eG0em31SurfYJ3D_dF9efm-vfV9_r217cfV4vb2jDKci2NBSHxyjaUNoYurdStZkKbTi4FF43gYEzHzVJy2pYS1-V3RM5gCxR4c1F9PfgO07KHlYGQR-3VMLpejzsVtVOnleA2ah23qu0I5ZgWg88PBmP8O0HKqnfJgPc6QJySIkII2XHBmoJ-_A-9i9NYRjxTUnQMs_aIWmsPygUbS18zm6pF23ZYNEzMbS-focpZQe9MDGBdyZ8IPh0JNqB93qTop3nu6RQkB9CMMaUR7NMwCFbzZqnDZik8R9kstS-aD8dTfFI8rlLzD9lZywM</recordid><startdate>20160330</startdate><enddate>20160330</enddate><creator>Upfill-Brown, Alexander M</creator><creator>Voorman, Arend</creator><creator>Chabot-Couture, Guillaume</creator><creator>Shuaib, Faisal</creator><creator>Lyons, Hil M</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0325-006X</orcidid></search><sort><creationdate>20160330</creationdate><title>Analysis of vaccination campaign effectiveness and population immunity to support and sustain polio elimination in Nigeria</title><author>Upfill-Brown, Alexander M ; Voorman, Arend ; Chabot-Couture, Guillaume ; Shuaib, Faisal ; Lyons, Hil M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-9cfe790df3223c2bf9a4a57ac89b767376ecc86cb9624a4a6a270192bf94e2e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Africa</topic><topic>Bayes Theorem</topic><topic>Care and treatment</topic><topic>Complications and side effects</topic><topic>Geographic information systems</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Initiatives</topic><topic>Nigeria - epidemiology</topic><topic>Poliomyelitis</topic><topic>Poliomyelitis - epidemiology</topic><topic>Poliomyelitis - immunology</topic><topic>Poliomyelitis - prevention &amp; control</topic><topic>Poliovirus Vaccine, Oral</topic><topic>Prospective Studies</topic><topic>Quality control</topic><topic>Vaccination</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Upfill-Brown, Alexander M</creatorcontrib><creatorcontrib>Voorman, Arend</creatorcontrib><creatorcontrib>Chabot-Couture, Guillaume</creatorcontrib><creatorcontrib>Shuaib, Faisal</creatorcontrib><creatorcontrib>Lyons, Hil M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Upfill-Brown, Alexander M</au><au>Voorman, Arend</au><au>Chabot-Couture, Guillaume</au><au>Shuaib, Faisal</au><au>Lyons, Hil M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis of vaccination campaign effectiveness and population immunity to support and sustain polio elimination in Nigeria</atitle><jtitle>BMC medicine</jtitle><addtitle>BMC Med</addtitle><date>2016-03-30</date><risdate>2016</risdate><volume>14</volume><issue>60</issue><spage>60</spage><epage>60</epage><pages>60-60</pages><artnum>60</artnum><issn>1741-7015</issn><eissn>1741-7015</eissn><abstract>The world is closer than ever to a polio-free Africa. In this end-stage, it is important to ensure high levels of population immunity to prevent polio outbreaks. Here, we introduce a new method of assessing vaccination campaign effectiveness and estimating immunity at the district-level. We demonstrate how this approach can be used to plan the vaccination campaigns prospectively to better manage population immunity in Northern Nigeria. Using Nigerian acute flaccid paralysis surveillance data from 2004-2014, we developed a Bayesian hierarchical model of campaign effectiveness and compared it to lot-quality assurance sampling data. We then used reconstructed sero-specific population immunity based on campaign history and compared district estimates of immunity to the occurrence of confirmed poliovirus cases. Estimated campaign effectiveness has improved across northern Nigeria since 2004, with Kano state experiencing an increase of 40 % (95 % CI, 26-54 %) in effectiveness from 2013 to 2014. Immunity to type 1 poliovirus has increased steadily. On the other hand, type 2 immunity was low and variable until the recent use of trivalent oral polio vaccine. We find that immunity estimates are related to the occurrence of both wild and vaccine-derived poliovirus cases and that campaign effectiveness correlates with direct measurements using lot-quality assurance sampling. Future campaign schedules highlight the trade-offs involved with using different vaccine types. The model in this study provides a novel method for assessing vaccination campaign performance and epidemiologically-relevant estimates of population immunity. Small-area estimates of campaign effectiveness can then be used to evaluate prospective campaign plans. This modeling approach could be applied to other countries as well as other vaccine preventable diseases.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>27029535</pmid><doi>10.1186/s12916-016-0600-z</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-0325-006X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1741-7015
ispartof BMC medicine, 2016-03, Vol.14 (60), p.60-60, Article 60
issn 1741-7015
1741-7015
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4812602
source MEDLINE; DOAJ Directory of Open Access Journals; SpringerNature Journals; PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Africa
Bayes Theorem
Care and treatment
Complications and side effects
Geographic information systems
Health aspects
Humans
Initiatives
Nigeria - epidemiology
Poliomyelitis
Poliomyelitis - epidemiology
Poliomyelitis - immunology
Poliomyelitis - prevention & control
Poliovirus Vaccine, Oral
Prospective Studies
Quality control
Vaccination
Vaccines
title Analysis of vaccination campaign effectiveness and population immunity to support and sustain polio elimination in Nigeria
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T19%3A26%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20of%20vaccination%20campaign%20effectiveness%20and%20population%20immunity%20to%20support%20and%20sustain%20polio%20elimination%20in%20Nigeria&rft.jtitle=BMC%20medicine&rft.au=Upfill-Brown,%20Alexander%20M&rft.date=2016-03-30&rft.volume=14&rft.issue=60&rft.spage=60&rft.epage=60&rft.pages=60-60&rft.artnum=60&rft.issn=1741-7015&rft.eissn=1741-7015&rft_id=info:doi/10.1186/s12916-016-0600-z&rft_dat=%3Cgale_pubme%3EA448073572%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1797850543&rft_id=info:pmid/27029535&rft_galeid=A448073572&rfr_iscdi=true